Scientists discover new cause of aggressive cancer in young people... and a possible treatment
Researchers in New York reviewed records from 11,000 cancer patients to evaluate long non-coding RNAs (lncRNAs), a type of RNA molecule that helps regulate gene behavior and distinguish healthy from non-healthy cells.
While studying human breast tumor models, they found a specific type of lncRNA called LINC01235, which has previously been linked to stomach cancer, may be feeding breast cancer cells.
The team tested their hypothesis using gene editing to 'turn off' LINC01235 in cells from triple-negative breast cancer (TNBC), an aggressive form of the disease that's resistant to standard hormonal treatments.
They found cancer cells without LINC01235 grew more slowly and were worse at forming tumors than those with the activated molecule.
The experts, from Cold Spring Harbor Laboratory on Long Island, believe LINC01235 activates another gene called NFIB, which has been shown to increase the risk of triple-negative breast cancer.
NFIB then controls how cells grow and develop, leading to them becoming cancer cells. By turning off the molecule (LINC01235) that encourages the TNBC-linked gene (NFIB) to proliferate, researchers believe it could inhibit tumor growth and spread.
Study researcher David Spector believes the findings could also lead to new treatments for triple-negative breast cancer, which accounts for 10 to 15 percent of breast cancer diagnoses and disproportionately is diagnosed in young women.
He said: 'Our long-term goal is to try to find an lncRNA or multiple lncRNAs that may eventually be therapeutic targets.'
Breast cancer is the most common cancer among women, affecting 316,000 per year and killing 42,000 in the US.
About to 10 to 15 percent of breast cancers are triple-negative, adding up to as many as 47,000 cases and 6,300 deaths.
Triple-negative means cancer cells don't have receptors that respond to the hormones estrogen and progesterone and the protein HER-2.
Without these receptors, triple-negative breast cancers don't respond to treatments that target those hormones, making them harder to treat.
Though the survival rate is over 90 percent if caught in earlier stages, those figures drop as low as 15 percent when the disease spreads to lymph nodes and other organs.
It's most common in Black women and those under 40 and is one of the many forms of the disease on the rise, along with colon and lung cancers.
In the new study, published in Molecular Cancer Research, tumor samples were taken from breast cancer patients in New York and used to make organoids, small models of tumors. They were then compared to healthy tissue samples.
The researchers found breast cancer tumors had significantly higher expressions of LINC01235 than healthy tissue.
LINC01235 was then deactivated with CRISPR, a type of gene editing that has mostly been tested in head, neck, gastrointestinal and brain cancers.
Since tumor growth slowed when researchers deactivated LINC01235, the team suspected the molecule increases the growth of breast cancer cells.
They suspected LINC01235 activates the gene NFIB, which has most often been tied to triple-negative breast cancer compared to other forms of breast cancer.
It's believed NFIB suppresses the expression of p21, a protein that inhibits cell growth.
With this protein suppressed, cancer cells can grow unchecked.
Lead researcher Wenbo Xu, a graduate student at Stony Brook University, said: 'Our findings demonstrate that LINC01235 positively regulates NFIB transcription.'
The team said the findings could be the first step in developing CRISPR technology to treat triple-negative breast cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
4 minutes ago
- BBC News
Wolverhampton supermarket hosts breast cancer screening unit
A breast cancer mobile screening unit is currently available outside a supermarket in Wolverhampton for women who are eligible for unit, stationed at Sainsbury's at Bentley Bridge until 15 September, marks the first time one has been located at the registered with GP practices in the local area and who are due a screening will receive an invitation by letter to attend the unit, and organisers hope it will encourage more local women to attend their aged 50 to 74 are eligible for breast screening and are invited every three years. The unit is run by the Dudley, Wolverhampton and South West Staffordshire Breast Screening Programme.A spokesperson for City of Wolverhampton Council said: "Attending screening is vital for early detection of breast cancer, which is strongly linked to reduced mortality."Anyone experiencing symptoms of breast cancer - such as a new lump, changes to the skin of the breast or nipple discharge - should not wait for their screening invitation but should instead contact their GP as soon as possible."Councillor Obaida Ahmed said: "Early detection is the best form of defence against cancer, which is why regular screening is so important. It can detect cancers at an early stage."Breast screening saves around 1,300 lives each year in the UK, and finding cancer early can make it more likely that treatment will be successful."Anyone who is invited for a screening appointment but is unable to attend their allocated time is advised to contact the screening programme's office on 01384 244177 to rebook an appointment at a more convenient time. Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram.
Reuters
5 minutes ago
- Reuters
Healthcare firms see growing activist investor involvement in the past year
Aug 20 (Reuters) - Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC (MDT.N), opens new tab In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR (AVTR.N), opens new tab Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES (CRL.N), opens new tab The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER ( opens new tab London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA (ILMN.O), opens new tab In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN (HSIC.O), opens new tab In January, private equity firm KKR (KKR.N), opens new tab built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER (PFE.N), opens new tab Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased, opens new tab its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE (KVUE.N), opens new tab In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH (CVS.N), opens new tab In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May.
Daily Mail
5 minutes ago
- Daily Mail
Urgent warning over common pain medicine after it triggered hallucinations and patient was misdiagnosed with schizophrenia
Doctors have sounded the alarm over a common daily pain drug amid fears it could trigger hallucinations in some patients. The medicine—known as Norco—is an opioid that interacts with parts of the brain that react to pain, helping to alleviate it. It is also prescribed occasionally to treat coughing and diarrhoea. Yet, medics have now discovered the drug may cause auditory and visual hallucinations when taken for prolonged period of time. Doctors labelled it a 'underreported' and 'misattributed' phenomenon, given it has only been documented in few medical reports. Their warning comes on the back of one American man who was misdiagnosed with schizophrenia after developing hallucinations while taking the drug. Writing in the journal Cureus, medics at Louisiana State University Health Sciences Centre, said the 67-year-old had reported auditory and visual hallucinations two years earlier, coinciding with beginning Norco for chronic back pain. It was only after the unidentified man from Shreveport in Louisiana, decided to stop taking the drug when he had increased his dose and the hallucinations suddenly became 'more vivid', that they stopped completely. The patient was suffering a range of serious medical conditions including coronary artery disease, high blood pressure, chronic back pain and hepatitis C. He was also a regular cigarette smoker and confessed to occasionally taking cannabis once or twice a month. He had no family history of mental health issues or dementia. But at the age of 63 he was hospitalised for a seizure and roughly three weeks later began experiencing visual hallucinations, doctors said. He reported seeing people trying to attack him and animals that weren't present and he was diagnosed with schizophrenia. Prescribed an antipsychotic medication, Quetiapine, this reduced his symptoms and aided his sleep. After two years on the drug, his dosage was lowered. During this time he began taking Norco in an effort to treat his chronic back pain. However, he soon began experiencing visual hallucinations again including seeing worms crawling across the roof of his house and reported feeling like someone was following him. After his back pain worsened, he also increased his intake of Norco to four tablets a day—still within the prescribed range. He sought help from a psychiatry clinic but also began to notice that the more Norco he took, the more vivid and intense the hallucinations became. Eventually, he decided to stop taking the drug and discovered his hallucinations also ended. 'The withdrawal of his medication settled his symptoms, and no further episodes of hallucinations or paranoia have presented since,' doctors wrote. 'While one of the common symptoms associated with schizophrenia is hallucinations, that alone does not mean one has schizophrenia. 'In the case of our patient, his hallucinations ceased when he stopped taking Norco.' The medics also noted that his first experience of hallucinations followed a seizure. 'Patients suffer a psychotic outbreak after undergoing a seizure cluster lasting several days,' they wrote. The state of mental disturbance that comes on after a seizure may leave the patient with confusion, dementia, hallucinations, delusions, and irritability,' Recreational cannabis also 'rarely induces full-blown psychosis', they added. Schizophrenia is also typically a condition that is diagnosed in early adulthood. 'A sudden onset of hallucinations and paranoia in a man in his mid-60s, especially without a family history of mental illness, should raise suspicion about alternative causes,' they concluded. Opioids can provide highly effective pain relief when used in the short-term. However, when used over longer periods they can lead to dependence, cause physical and mental health issues, or even death from accidental overdoses or heart conditions resulting from side effects. Health officials have long advised that Norco, which contains the substances hydrocodone and acetaminophen, should not be taken for prolonged periods of time. According to the US medicines regulator, the Food and Drugs Administration, Norco 'exposes patients and other users to the risks of opioid addiction, abuse and misuse, which can lead to overdose and death'. High-dose opioids have also been reported to more likely result in 'neurotoxic effects including hallucinations', studies have suggested. But last year, analysis showed that NHS spending on addictive opioid painkillers had doubled since the pandemic. Research also showed that longer waiting times for routine care, such as hip and knee replacements, triggered by Covid lockdowns caused a 40 per cent increase in prescriptions for highly addictive opioids. Experts warned that many were reliant on the powerful drugs to get by, leaving them at risk of developing an addiction that continues even after their operation. Symptoms of schizophrenia usually begin between ages 16 and 30. They include hallucinations, muddled thoughts and speech and wanting to avoid people. Figures suggest around 1 per cent of the world population suffers from the condition, including around 685,000 in the UK and two million in the US. The cause of schizophrenia is not understood and it is believed to be a mix of genetics, abnormalities in brain chemistry and/or possible viral infections and immune disorders.
